Literature DB >> 20519352

The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma.

Etienne Cavalier1, Adrian F Daly, Daniela Betea, Pamela Nicoleta Pruteanu-Apetrii, Pierre Delanaye, Phil Stubbs, Arthur R Bradwell, Jean-Paul Chapelle, Albert Beckers.   

Abstract

BACKGROUND: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which is recognized by third-generation but not by second-generation PTH immunoassays. In normal individuals, the third-generation to second-generation PTH ratio should be less than 1.
OBJECTIVE: Our objective was to study the utility of the third-generation to second-generation PTH ratio as a means of distinguishing PCa patients (n=24) from control groups with and without disorders of calcium secretion, including patients on renal hemodialysis (n=74), postrenal transplantation (n=60), and primary hyperparathyroidism (PHP; n=30). SETTING AND
DESIGN: We conducted a retrospective, laboratory-based study at tertiary referral academic centers.
RESULTS: The mean third-generation to second-generation ratio was 0.58+/-0.10 in the dialysis patients, 0.54+/-0.10 in the renal transplant group, 0.54+/-0.12 in the elderly healthy patients, and 0.68+/-0.11 in the PHP group. All 245 of these patients presented a PTH third-generation to second-generation ratio of less than 1. In contrast, we observed an inverted third-generation to second-generation PTH ratio of more than one in 20 PCa patients, whereas only four PCa patients had a normal ratio of less than 1.
CONCLUSIONS: An inverted third-generation to second-generation PTH ratio occurred in the majority of patients with advanced PCa and was absent in all 245 relevant controls. A third-generation to second-generation PTH ratio higher than 1 had a sensitivity of 83.3% and a specificity of 100% among PHP patients as a marker for PCa. This ratio may be useful to identify patients with PCa earlier and to detect patients either at risk of developing PCa or those in whom recurrence is taking place.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519352     DOI: 10.1210/jc.2009-2791

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

2.  Radiofrequency ablation of parathyroid adenoma in primary hyperparathyroidism.

Authors:  Byung Seup Kim; Tae Ik Eom; Kyung Ho Kang; Sung Jun Park
Journal:  J Med Ultrason (2001)       Date:  2013-09-20       Impact factor: 1.314

Review 3.  How the reference values for serum parathyroid hormone concentration are (or should be) established?

Authors:  J-C Souberbielle; F Brazier; M-L Piketty; C Cormier; S Minisola; E Cavalier
Journal:  J Endocrinol Invest       Date:  2016-10-01       Impact factor: 4.256

Review 4.  Diagnosis and management of parathyroid cancer.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Endocrinol       Date:  2012-07-03       Impact factor: 43.330

5.  Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation.

Authors:  Philippe Caron; William F Simonds; Jean-Christophe Maiza; Mishaela Rubin; Tom Cantor; Louise Rousseau; John P Bilezikian; Jean-Claude Souberbielle; Pierre D'Amour
Journal:  Clin Endocrinol (Oxf)       Date:  2011-06       Impact factor: 3.478

Review 6.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

Review 7.  High-Resolution Mass Spectrometry for the Measurement of PTH and PTH Fragments: Insights into PTH Physiology and Bioactivity.

Authors:  Candice Z Ulmer; Kittrawee Kritmetapak; Ravinder J Singh; Hubert W Vesper; Rajiv Kumar
Journal:  J Am Soc Nephrol       Date:  2022-04-08       Impact factor: 14.978

Review 8.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

9.  The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM.

Authors:  Etienne Cavalier; Samuel Vasikaran; Harjit P Bhattoa; Annemieke C Heijboer; Konstantinos Makris; Candice Z Ulmer
Journal:  Clin Chim Acta       Date:  2021-01-04       Impact factor: 3.786

10.  Long-term remission of disseminated parathyroid cancer following immunotherapy.

Authors:  Marta Sarquis; Stephen J Marx; Albert Beckers; Arthur R Bradwell; William F Simonds; Maria Aparecida C Bicalho; Adrian F Daly; Daniela Betea; Eitan Friedman; Luiz De Marco
Journal:  Endocrine       Date:  2019-11-28       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.